These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25085582)

  • 21. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
    He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
    Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
    Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
    Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
    Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
    Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
    Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
    Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
    Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced antitumor activity by combining an adenovirus harboring ING4 with cisplatin for hepatocarcinoma cells.
    Xie Y; Sheng W; Miao J; Xiang J; Yang J
    Cancer Gene Ther; 2011 Mar; 18(3):176-88. PubMed ID: 21052098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model.
    Miyake H; Hara I; Hara S; Arakawa S; Kamidono S
    Urology; 2000 Aug; 56(2):332-6. PubMed ID: 10925118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer therapy utilizing an adenoviral vector expressing only E1A.
    Hubberstey AV; Pavliv M; Parks RJ
    Cancer Gene Ther; 2002 Apr; 9(4):321-9. PubMed ID: 11960282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24.
    Wu YM; Zhang KJ; Yue XT; Wang YQ; Yang Y; Li GC; Li N; Wang YG
    Acta Pharmacol Sin; 2009 Apr; 30(4):467-77. PubMed ID: 19270721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic efficacy of an hTERT promoter-driven oncolytic adenovirus that expresses apoptin in gastric carcinoma.
    Liu L; Wu W; Zhu G; Liu L; Guan G; Li X; Jin N; Chi B
    Int J Mol Med; 2012 Oct; 30(4):747-54. PubMed ID: 22842823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
    Doloff JC; Jounaidi Y; Waxman DJ
    Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
    Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
    Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter.
    Seo HK; Seo JB; Nam JK; Jeong KC; Shin SP; Kim IH; Lee SD; Lee SJ
    Oncotarget; 2014 Jul; 5(14):5615-23. PubMed ID: 25015402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
    Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
    Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
    Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
    Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting gene expression of the mouse uroplakin II promoter to human bladder cells.
    Zhu H; Zhang ZA; Xu C; Huang G; Zeng X; Wei S; Zhang Z; Guo Y
    Urol Res; 2003 Mar; 31(1):17-21. PubMed ID: 12624658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.
    Meng HT; Li L; Liu H; Wang Y; Li GC; Qian WB
    Acta Pharmacol Sin; 2009 Nov; 30(11):1529-36. PubMed ID: 19820719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.